Uploaded May 2022 | Updated November 2026, 8 hours ago
Waiting twenty years for your discovery to gain FDA approval might test some researchers' resolve. But Mark Goodman, kept his eye on the prize: a new and improved imaging agent. We created a molecule, FACBC, and studied it in cancer cell. We discovered that the radiotracer was especially good for looking at prostate cancer and superior to the current imaging agent. With the construction of a new research building and radiopharmacy lab inventor meets patient.
Learn more here: https://www.ott.emory.edu/about/success/axumin.html
Waiting twenty years for your discovery to gain FDA approval might test some researchers' resolve. But Mark Goodman, kept his eye on the prize: a new and improved imaging agent. We created a molecule, FACBC, and studied it in cancer cell. We discovered that the radiotracer was especially good for looking at prostate cancer and superior to the current imaging agent. With the construction of a new research building and radiopharmacy lab inventor meets patient.
Learn more here: https://www.ott.emory.edu/about/success/axumin.html










